Median Technologies
Focus: Median Technologies is a Shanghai-headquartered biotech company specializing in imaging phenomics with a focus on oncology applications. Founded in 2024 and already public, the company operates at an early stage with a lean pipeline focused on lung cancer and high-risk cancer screening.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Median Technologies
AI assessmentNot HiringNo open roles listed right now. Follow Median Technologies to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Median LCS
High Risk CancerClinical Trials (1)
NCT06576232Standalone Observational Study Assessing the Performance of an AI/ML Tech-based SaMD on Chest LDCT Images (REALITY)
N/AHelp build intelligence for Median Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.